Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer

Hu, Jiao; Yu, Anze; Othmane, Belaydi; Qiu, Dongxu; Li, Huihuang; Li, Chao; Liu, Peihua; Ren, Wenbiao; Chen, Minfeng; Gong, Guanghui; Guo, Xi; Zhang, Huihui; Chen, Jinbo; Zu, Xiongbing

doi:10.7150/thno.53649

Public

Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer

Published in Theranostics • Jan 1, 2021

Authors:

Jiao Hu

Anze Yu

Belaydi Othmane

Abstract

Anti-Siglec15 immunotherapy might be suitable for BLCA treatment as Siglec15 correlates with a non-inflamed TME in BLCA. Siglec15 could also predict the molecular subtype and the response to several treatment options.

Subject

Bladder cancer

Immunotherapy

Immune system

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!